Key Points
- Insider sale: Traci Umberger sold 100,000 KMTS shares for approximately $2.72 million, reducing her direct holdings by 33.8% to 195,825 shares.
- Financial performance: Kestra reported quarterly revenue of $30.97 million but posted an EPS loss of $0.75, missing estimates by $0.14. Analysts expect a full-year loss of $2.45 per share.
- Analyst outlook: Ratings are mixed, but the stock carries a consensus “Moderate Buy” rating and a $29 price target; shares recently opened at $28.32, near their 52-week high of $30.00.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Webster sold 15,000 shares of the business's stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $29.56, for a total value of $443,400.00. Following the completion of the transaction, the insider directly owned 445,215 shares of the company's stock, valued at approximately $13,160,555.40. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Brian Daniel Webster also recently made the following trade(s):
- On Monday, August 17th, Brian Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $27.48, for a total value of $412,200.00.
- On Tuesday, August 4th, Brian Webster sold 51,900 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00.
- On Monday, August 3rd, Brian Webster sold 13,017 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.92, for a total value of $311,366.64.
- On Friday, July 31st, Brian Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total value of $202,224.80.
- On Thursday, July 30th, Brian Webster sold 7,857 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.72, for a total transaction of $178,511.04.
Kestra Medical Technologies Stock Up 3.7%
KMTS stock opened at $28.32 on Friday. The firm has a 50-day simple moving average of $26.42 and a two-hundred day simple moving average of $23.79. Kestra Medical Technologies, Ltd. has a one year low of $17.34 and a one year high of $30.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). The firm had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. As a group, research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.
Institutional Trading of Kestra Medical Technologies
Large investors have recently bought and sold shares of the stock. Sterling Capital Management LLC grew its position in Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock worth $25,000 after purchasing an additional 784 shares during the last quarter. Quantinno Capital Management LP acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth $431,000. California State Teachers Retirement System lifted its stake in shares of Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock worth $555,000 after buying an additional 7,844 shares during the period. Spartan Wealth Advisory Services LLC purchased a new stake in shares of Kestra Medical Technologies during the first quarter valued at $603,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock valued at $1,397,000 after buying an additional 22,471 shares during the last quarter.
Analyst Ratings Changes
Several brokerages have recently commented on KMTS. Wall Street Zen lowered Kestra Medical Technologies from a "hold" rating to a "sell" rating in a report on Saturday, September 12th. Piper Sandler reissued an "overweight" rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Weiss Ratings upgraded Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 16th. Royal Bank Of Canada set a $30.00 target price on Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a "market perform" rating for the company. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.00.
Read Our Latest Stock Report on Kestra Medical Technologies
About Kestra Medical Technologies
(
Get Free Report)
Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.
The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
